Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The company offers a cloud-based data and analytics platform, software applications, and expertise to help clients manage data, derive analytical insights, and achieve clinical, financial, and operational improvements. Its core solution includes the Ignite Data & Analytics Platform, which integrates data from disparate software systems, and a suite of analytics applications focused on Clinical Improvement, Revenue & Cost Improvement, Ambulatory Operations, Measures & Registries, and Data & Analytics. The company also provides services such as data and analytics services, domain expertise, education, Tech-Enabled Managed Services (TEMS), and implementation. Health Catalyst serves primarily healthcare providers, including health systems, to support data-informed decision-making across their operations.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Health Information Services Homepage healthcatalyst.com
Sector Healthcare IR page ir.healthcatalyst.com
Tags
healthcare analytics, clinical improvement, revenue cycle management, data integration, cloud-based platform, managed services, ambulatory operations, healthcare it, Ignite Data & Analytics Platform, Ignite, Tech-Enabled Managed Services, TEMS
Press page —

Metrics

Valuation  
Market cap $ 105.795M
Market cap (USD) $ 105.795M
P/E -0.49
PEG —
P/BV 0.73
P/S 0.39
P/OCF 3.94
P/FCF 4.04
Dividend yield —
Turnover / mcap —
Returns  
ROE -58.3%
ROI -44.6%
ROIC -30.2%
Profit margin -57.2%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 152.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 13
Quality score -11.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 311.136M 306.584M 295.938M 276.236M 241.926M 188.845M 154.941M 112.574M
Net profit -177.974M -69.502M -118.147M -137.403M -153.21M -115.017M -60.096M -61.984M
Free cash flow -237K 12.943M -34.316M -37.437M -33.573M -33.923M -34.583M -42.571M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 2.39 7.07 9.26 10.63 39.62 43.53 34.7 —
Price performance 12m -0.66 -0.24 -0.13 -0.73 -0.09 0.25 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 27.7M 27.6M 48.3M 48.8M 48M 60.3M 57.2M 59.1M
↳ YoY growth -0.5% +75.2% +1.0% -1.7% +25.7% -5.2% +3.4%
↳ 5y CAGR +16.8% +15.7% +4.1%
Borrowings, current (USD) — — 1.29M 0.00 — — — 0.00 231M 1.63M
Borrowings, non-current (USD) — — 18.8M 48.2M 169M 181M 227M 228M 151M 152M
Lease liabilities (USD) — — 6.81M 4.46M 26.3M 23.7M 21.5M 21M 19.9M 18M
Cash and deposits (USD) 12.5M 23M 28.4M 18M 92M 193M 116M 106M 250M 50.8M
Intangible assets (USD) — — 28.3M 25.5M 98.9M 105M 92.2M 73.4M 86.1M 77.7M
Right-of-use assets (USD) — — 6.34M 3.79M 24.7M 21.1M 16.7M 13.9M 12.1M 6.64M
Net debt (borrowings + leases - cash) (USD) — — -1.53M 34.6M 103M 11.4M 132M 143M 153M 120M
Cash flow detail
Operating cash flow (USD) — -36.8M -40.3M -32.2M -26.1M -23.1M -35.3M -33.1M 14.6M 731,000
Purchases of property, plant and equipment (USD) — -2.47M -2.28M -2.4M -7.78M -10.5M -2.17M -1.24M -1.62M -968,000
Purchases of intangible assets (USD) — -878,000 -228,000 -1.94M -1.25M -1.37M -2.26M -1.12M -508,000 -805,000
Change in receivables (cash effect) (USD) — 4.44M -3.63M 127,000 -16.4M 102,000 788,000 -13.7M 4.28M -1.81M
Share buybacks (cash effect) (USD) — 0.00 -8.71M 0.00 0.00 0.00 -8.39M -1.81M 0.00 -5M
Interest paid (cash effect) (USD) — -1.03M -3.94M -5.56M -4.98M -6.36M -5.75M -5.75M -10.1M -21.9M
Income taxes paid (cash effect) (USD) — -66,000 -31,000 -19,000 -92,000 -138,000 -297,000 -266,000 -269,000 -395,000
Share-based compensation (USD) — 4.24M 4.2M 17.8M 38M 65.1M 72.1M 55.8M 40.1M 27M
Operating cash flow before change in receivables (USD) — -41.3M -36.7M -32.3M -9.7M -23.2M -36.1M -19.4M 10.3M 2.54M
Free cash flow (OCF - PPE - intangibles) (USD) — -40.2M -42.8M -36.5M -35.2M -34.9M -39.7M -35.4M 12.4M -1.04M
Income detail
Research and development expense (USD) — 28.5M 38.6M 46.3M 53.5M 62.7M 75.7M 72.6M 58M 49.8M
↳ 5y CAGR +21.6% +13.5% +4.6% -1.4%
Total comprehensive income (USD) — -47M -62M -60M -115M -153M -138M -117M -70.4M -176M
Comprehensive income to owners (USD) — -47M -62M -60M -115M -153M -138M -117M -70.4M -176M
Provision for credit losses (USD) — — — — 863,000 499,000 691,000 1.82M 1.2M 1.5M
Credit cost ratio (credit losses / average receivables) (%) — — — — 2.3% 1.0% 1.4% 3.4% 2.0% 2.6%
Reported Feb 28, 2020 Feb 28, 2020 Feb 28, 2020 Feb 28, 2020 Feb 25, 2021 Feb 28, 2023 Feb 28, 2023 Nov 7, 2024 Feb 26, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Health Catalyst Reports Third Quarter 2026 Results Bull 3 Bear 4 Results

SALT LAKE CITY, UT, November 5, 2026 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for the quarter ended September 30, 2026.

“We delivered a third quarter above the high end of our revenue and Adjusted EBITDA guidance, and we are reaffirming our full-year outlook,” said Simeon Kohl, President and Chief Executive Officer of Health Catalyst. “Our immediate priority is to strengthen the foundation of the business, with a focus on retaining the clients we serve and developing a path to generating durable, profitable revenue.”

Financial Highlights for the Three Months Ended September 30, 2026

Key Financial Metrics

Three Months Ended September 30, Year over Year Change

2026(2)

2025

GAAP Financial Measures: (in thousands, except percentages, unaudited)

Total revenue $ 56,283 $ 76,323 (26)%

Gross profit

$ 17,345 $ 29,979 (42)%

Gross margin

31 % 39 %

Net income (loss) $ 40,496 $ (22,229) 282%

Non-GAAP Financial Measures:(1)

Adjusted Gross Profit

$ 24,913 $ 40,133 (38)%

Adjusted Gross Margin

44 % 53 %

Adjusted EBITDA $ 779 $ 12,0

October 22, 2026 at 4:05 PM EDT

SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, will release its third quarter 2026 operating results on Thursday, November 5, 2026, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.

Conference Call Details

The conference call can be accessed by dialing 800-274-8461 for U.S. participants, or 203-518-9814 for international participants, and referencing conference ID “HCATQ326.” A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Health Catalyst

Health Catalyst, Inc. (Nasdaq: HCAT) is a healthcare intelligence company designed to accelerate measurable improvement for health systems across cost, clinical, and consumer performance. Backed by deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes, Health Catalyst helps health systems move from data to confident, measurable action.

Health Catalyst Investor Relations Contact:

Stephanie St. Clair Finance and Investor Relations, SVP [email protected]

Health Catalyst Media Contact:

Kay Blazar VP, PR SVM PR & Marketing [email protected]

September 14, 2026 at 4:19 PM EDT

Reller Joins Health Catalyst as it Enters Its Next Phase of Growth

SALT LAKE CITY, Sept. 14, 2026 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst", NASDAQ: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Tami Reller has been appointed to its board of directors (Board), effective October 1, 2026. Reller will serve as audit chair and as a member of its compensation committee, also effective October 1, 2026.

Health Catalyst

Reller's appointment follows the naming of Simeon Kohl as Chief Executive Officer and President, effective September 14, 2026. Under Kohl's leadership, Health Catalyst will continue advancing its highest-conviction technologies, positioning Health Catalyst as an AI-forward healthcare intelligence company built on 18 years of results and $2.8 billion in validated outcomes. Its technology, paired with leading healthcare expertise, helps solve health systems' hardest problems across cost, clinical, and consumer performance.

"How we build this board reflects where we believe Health Catalyst is headed," said Justin Spencer, Chairman of the Board of Health Catalyst. "Reller has guided public companies through periods of growth, has deep financial expertise, and has spent years operating where healthcare and technology meet, including on the healthcare delivery side. As the company continues to execute a focused strategy and invest in what's ahead, we're energized about this next chapter. Reller brings exactly the experience we need now."

Reller previously served in various leadership roles at Duly Health and Care, leading one of the largest independent physician groups in the U.S., including President from 2021 to 2022, CEO from 2022 to 2023 and executive chair from 2023 to 2024. Reller has spent decades at the intersection of healthcare and technology, with leadership experience in finance, growth, oper­a­tions, mar­ket­ing and con­sumer expe­ri­ence. She previously worked as a senior executive at Microsoft and held multiple leadership roles at various subsidiaries of UnitedHealth Group, including executive vice president and chief marketing and experience officer of UnitedHealthcare and chief growth officer, chief financial officer, and chief marketing officer of Optum.

Reller also brings extensive public-company board experience, having served as a member of the board of directors of SPS Commerce, Inc. (NASDAQ) since 2016, including as a member of the audit committee, governance and nominating committee and five years as board chair, and between 2014 and 2022 served as a member of the board of directors of Avalara Inc. until its acquisition (formally NASDAQ), including service as a member of Avalara's audit committee and compensation committee. She has also served on non-profit boards, including the Seattle Children's Hospital Foundation, where she also served as Treasurer, and Fairview Health Services, a Minnesota-based nonprofit health system.

"I've spent my career on both sides of the technology and healthcare equation, including time on the healthcare delivery side, and I know what it takes to make technology truly deliver for a health system," said Reller. "Health Catalyst has the data, the proven results, and the focus — and from where I've sat on the health system side, I believe this is the moment for that experience to have great impact. That's why I wanted to join, and I'm eager to help the company deliver that impact."

About Health Catalyst

Health Catalyst, Inc. (NASDAQ: HCAT) is a healthcare intelligence company designed to accelerate measurable improvement for health systems across cost, clinical, and consumer performance. Backed by deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes, Health Catalyst helps health systems move from data to confident, measurable action.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the impact of Reller's appointment as a member of the Board, and future performance and opportunities of Health Catalyst. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market or industry conditions, regulatory environment, and receptivity to our technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key clients or partners, clients reducing or eliminating their spend with us, client churn or down-selling in connection with the migration to Ignite or otherwise; (v) fluctuations in our project-based, non-recurring revenue, (vi) macroeconomic challenges (including high inflationary and/or high interest rate environments, tariffs, or market volatility and measures taken in response thereto), natural disasters or any new public health crises, and regional or global conflicts (including in the Middle East); (vii) the divestiture of Vitalware may not achieve some or all of the expected benefits and may adversely affect our business; and (viii) changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our reports filed with the Securities Exchange Commission (SEC), including, but not limited to the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, filed with the SEC on August 6, 2026, and the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026 and amended on April 30, 2026. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.

Health Catalyst Investor Relations Contact Stephanie St. Clair Finance and Investor Relations, SVP +1 (855)-309-6800 [email protected]

Health Catalyst Media Contact Kay Blazar VP, PR SVM PR & Marketing [email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/health-catalyst-strengthens-its-board-with-the-appointment-of-tami-reller-302878077.html

SOURCE Health Catalyst

Prompts

Health Catalyst, Inc (ticker HCAT), listed in United States.

Company History

Date Change Detail
Oct 13, 2017 Renamed HQC Holdings, Inc. → HEALTH CATALYST, INC.

ETFs Holding Health Catalyst, Inc

ETF Weight in ETF Shares Market value As of
MEDI 0.40% 119,131 $ 162.018K Nov 12, 2026
FESM 0.01% 391,022 $ 778.134K Jun 30, 2026
AVUV 0.00% 3,940 $ 5,437.20 Nov 16, 2026